CA3200232A1 - Inhibiteurs de cd73 et leurs utilisations pharmaceutiques - Google Patents

Inhibiteurs de cd73 et leurs utilisations pharmaceutiques

Info

Publication number
CA3200232A1
CA3200232A1 CA3200232A CA3200232A CA3200232A1 CA 3200232 A1 CA3200232 A1 CA 3200232A1 CA 3200232 A CA3200232 A CA 3200232A CA 3200232 A CA3200232 A CA 3200232A CA 3200232 A1 CA3200232 A1 CA 3200232A1
Authority
CA
Canada
Prior art keywords
unsubstituted
substituted
compound
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3200232A
Other languages
English (en)
Inventor
Yuhua Zhang
Chuanhao HUANG
Xianqi Kong
Gang Chen
Jiasheng LU
Qiguo Zhang
Dawei Chen
Xingwu ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Risen Suzhou Pharma Tech Co Ltd
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/133,348 external-priority patent/US11530234B2/en
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of CA3200232A1 publication Critical patent/CA3200232A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés inhibiteurs de la CD73 (également connue sous le nom d'ecto-5-nucléotidase) ainsi que des compositions et des utilisations de ceux-ci pour traiter ou prévenir des maladies, troubles et affections associés ou afférents à la CD73, y compris des troubles liés au cancer et à l'immunité. Les composés inhibiteurs de la CD73 comprennent des composés ayant La structure représentée par la formule I': (I') et des esters ou des sels pharmaceutiquement acceptables de ceux-ci.
CA3200232A 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques Pending CA3200232A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011346141 2020-11-25
US17/133,348 US11530234B2 (en) 2018-09-11 2020-12-23 CD73 inhibitors and pharmaceutical uses thereof
PCT/CA2021/051688 WO2022109741A1 (fr) 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques

Publications (1)

Publication Number Publication Date
CA3200232A1 true CA3200232A1 (fr) 2022-06-02

Family

ID=81753702

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3200232A Pending CA3200232A1 (fr) 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques

Country Status (5)

Country Link
EP (1) EP4251633A4 (fr)
CN (1) CN116546990A (fr)
AU (1) AU2021389685A1 (fr)
CA (1) CA3200232A1 (fr)
WO (1) WO2022109741A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025260011A1 (fr) * 2024-06-14 2025-12-18 Alnylam Pharmaceuticals, Inc. Monomères modifiés en 5', oligonucléotides et arn double brin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225229A1 (fr) * 2007-11-26 2010-09-08 Pfizer Inc. Dérivés de pyrazole comme inhibiteurs de 5-lo
WO2017120508A1 (fr) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulateurs de l'ecto-5 '-nucléotidase et leur utilisation
WO2018094148A1 (fr) * 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibiteurs de l'immunosuppression médiée par cd73
IL304348B2 (en) * 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
MX2021002878A (es) * 2018-09-11 2021-08-16 Risen Suzhou Pharma Tech Co Ltd Inhibidores de cd73 y usos farmaceuticos de los mismos.
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
CN114539340B (zh) * 2020-11-25 2024-06-07 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用

Also Published As

Publication number Publication date
CN116546990A (zh) 2023-08-04
WO2022109741A1 (fr) 2022-06-02
EP4251633A1 (fr) 2023-10-04
AU2021389685A9 (en) 2024-02-08
AU2021389685A1 (en) 2023-07-06
EP4251633A4 (fr) 2024-09-25

Similar Documents

Publication Publication Date Title
KR102853140B1 (ko) Cd73 억제제 및 그의 제약 용도
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
TWI781960B (zh) 腺核苷5'-核苷酸酶之抑制劑及相關用途
EP3399984B1 (fr) Modulateurs de l'ecto-5 '-nucléotidase et leur utilisation
AU2026201609A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
AU2019339924C1 (en) CD73 inhibitors and pharmaceutical uses thereof
WO2024119277A1 (fr) Inhibiteurs de kras et leurs utilisations pharmaceutiques
CA3082351A1 (fr) Composes modulateurs de sting, et procedes de fabrication et d'utilisation
SG193002A1 (en) Dispiropyrrolidine derivative
ES3008927T3 (en) Process for preparing modulators of p300 and/or cbp
KR20170109546A (ko) Irak1/4 억제제로서의 매크로시클릭 화합물 및 이들의 용도
EP3560921B1 (fr) Composé de quinazoline et procédé de préparation, utilisation en tant qu'inhibiteur de pi3k pour le traitement des maladies de cancer et composition pharmaceutique correspondantes
JP2022529152A (ja) Ｃｄ７３阻害剤
US20240024346A1 (en) Cd73 inhibitors and pharmaceutical uses thereof
CA3200232A1 (fr) Inhibiteurs de cd73 et leurs utilisations pharmaceutiques
US11530234B2 (en) CD73 inhibitors and pharmaceutical uses thereof
US20230295213A1 (en) Cd73 inhibitors and pharmaceutical uses thereof
CA3136366A1 (fr) Inhibiteurs de cd73
WO2001042256A1 (fr) ANALOGUES DE (1S, cis)-4-(2-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL EN TANT QU'ANTIVIRAL
HK40024456B (en) 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241107

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251103

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251118

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260115

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260116